ACCB Biotech
Beijing · Founded 2004
About ACCB Biotech
Beijing ACCB Biotech Ltd. (Θ¢àσ║╖σìÜτöƒτë⌐) is focused on the research and development of cancer detection methods through the application of molecular biology technologies. Based on the concept of personalized therapy, the company provides detection services that include early-cancer screening, drug selection, effect tracking, prognostic evaluation, transfer and recurrence monitoring, and other testing services. ACCB Biotech’s product series include EnzymAct, Baikangan, Gene 21 of Breast Cancer, automated workstation for nucleic acid extraction, and more. The company now has production, research and development, and service facilities of more than 3,000 square meters, and its cleanliness attains the criteria of 10,000 grades. In June, 2009, EnzymAct® was successfully approved by the State Food and Drug Administration.
Company Facts
- Founded: 2004
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Estimated revenue: Less than $1M
- Total funding: $1.1M
- Funding stage: Private Equity
- Last round: Private Equity (Nov 2020)
- Website: http://www.accb.com.cn
- Phone: +86 10 6279 0729
Industries & Categories
Biotechnology, Genetics, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/accb-biotech-2808720 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.